Laura Ferguson, NP
Family · Columbus, MSNPI 1154791028
Payments from drug & device makers
Across 394 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1000
- Sanofi$575
- Boehringer Ingelheim$270
- Verona Pharma, Inc.$235
- Grifols USA, LLC$233
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,67999%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $1,431 |
| GSK | 79 | $1,000 |
| Sanofi | 34 | $575 |
| Boehringer Ingelheim | 15 | $270 |
| Verona Pharma, Inc. | 21 | $235 |
| Grifols USA, LLC | 11 | $233 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $212 |
| Mylan Specialty L.p. | 9 | $193 |
| Mallinckrodt Hospital Products Inc. | 12 | $191 |
| Fresenius USA Marketing, Inc. | 13 | $190 |
| Dendreon Pharmaceuticals LLC | 6 | $170 |
| United Therapeutics Corporation | 10 | $167 |
| Insmed, Inc. | 10 | $161 |
| Regeneron Healthcare Solutions, Inc. | 8 | $159 |
| Viatris Specialty LLC | 11 | $153 |
| Merck | 8 | $152 |
| Bayer | 8 | $132 |
| Baxter Healthcare | 5 | $131 |
| Myriad Genetic Laboratories, Inc. | 7 | $127 |
| Philips North America LLC | 7 | $124 |
| Amgen | 7 | $118 |
| Boston Scientific | 1 | $101 |
| Vifor Pharma, Inc. | 4 | $85 |
| Pfizer | 4 | $82 |
| AbbVie | 6 | $78 |
| Electromed, Inc. | 3 | $50 |
| Coloplast | 3 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Urovant Sciences Inc | 2 | $26 |
| Akebia Therapeutics Inc | 1 | $25 |
| Hollister Incorporated | 1 | $22 |
| Convatec Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$123
- AIRSUPRA$123
- BREZTRI$123
- GENERAL - THERAPIES$101
How this compares
$6,734 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 656 | $444,990 |
| OfevNintedanib Esylate | 28 | $364,085 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 311 | $208,202 |
| Dupixent PenDupilumab | 41 | $158,067 |
| Fasenra PenBenralizumab | 19 | $106,710 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 181 | $90,192 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 71 | $39,636 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $23,097 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $17,807 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $15,845 |
| Spiriva RespimatTiotropium Bromide | 27 | $15,820 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 524 | $13,417 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 32 | $13,397 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $5,514 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,000 | $563,709909 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $270 | $437,349152 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,431 | $237,443397 claims |
| MerckDulera | $152 | $4,48211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Columbus
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.